. home.aspx



PDS Biotechnology Announces Publication Supporting Novel Mechanisms

May 15, 2019 / globenewswire

PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of multifunctional immunotherapeutic products, today announced a peer-reviewed publication supporting the novel mechanisms of action of its proprietary Versamune® platform in cancer immunotherapy. The article “Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response” was published online on May 3, 2019 in the Journal of Immunology, and describes the way PDS’ Versamune® platform recruits and activates killer T-cells to recognize and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack. The article will appear in print in the June 2019 issue of the Journal. Dr. Lauren V. Wood, MD, PDS Biotechnology’s Chief Medical Officer, commented: "As a cancer immunologis...